Chest
Clinical InvestigationsCOPDCardiovascular Safety of Salmeterol in COPDa
Section snippets
Materials and Methods
A pooled analysis of cardiovascular safety data was conducted to assess the effects of therapy with salmeterol, 50 μg bid, on the cardiovascular system in patients with COPD. In order to conduct a pooled analysis, individual patient data are required. A total of 17 clinical studies of salmeterol treatment in COPD patients were considered for inclusion because of the availability of individual patient data. Further prospectively defined inclusion criteria included the following: sponsorship by
Results
A total of 1,443 patients received placebo, while 1,410 patients were treated with salmeterol, 50 μg bid. The data are presented only for the ITT population since the findings in the PR population were similar to those in the ITT population. Although some differences were observed among subgroups when compared to the overall ITT population (data for these differences are presented), the findings across subgroups were comparable between the salmeterol and placebo groups. Only significant results
Discussion
Traditionally, treatment options have been fairly limited for patients with COPD. However, the use of salmeterol, a relatively new agent that has been indicated for the treatment of COPD, has resulted in considerable clinical benefits. Significant improvements in lung function, dyspnea ratings, and exercise performance have been reported in patients with COPD treated with salmeterol.461314In one comparative study6with ipratropium bromide, salmeterol significantly reduced the time to first
Acknowledgment
We thank Tracy Weeks and Shehnaz Gangjee, PhD, for assistance with the preparation of this manuscript.
References (23)
- et al.
Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease
Pulm Pharmacol
(1994) - et al.
Efficacy of salmeterol xinafoate in the treatment of chronic obstructive pulmonary disease
Chest
(1999) - et al.
Cardiac effects of formoterol and salmeterol in patients suffering from COPD with pre-existing cardiac arrhythmias and hypoxemia
Chest
(1998) - et al.
The QTc interval, autonomic neuropathy and mortality in hypoxemic COPD
Respir Med
(1995) - et al.
Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability
Am Heart J
(1996) - et al.
Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease
Respir Med
(1998) - et al.
Salmeterol reduces dyspnea and improves lung function in patients with COPD
Chest
(1997) - et al.
Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease
Clin Ther
(1998) - et al.
Cardiac arrhythmia in patients with mild-to-moderate obstructive pulmonary disease: comparison of beta-agonist therapy alone and in combination with a xanthine derivative, enprophylline or theophylline
Chest
(1985) - et al.
Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease
Chest
(1993)
Beta-adrenoceptor blocking drugs: adverse reactions and drug interactions
Pharmacol Ther
Cited by (95)
Effect of long-acting β <inf>2</inf> -agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients
2018, Pulmonary Pharmacology and TherapeuticsAcute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study
2017, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :For the primary objective, non-inferiority between the DPI and pMDI formulations was to be demonstrated at each dose level if the upper bound of the 95% CI did not exceed 5 bpm, using data from the pharmacodynamic (PD) population. The 5 bpm upper non-inferiority margin was consistent with two previous cardiovascular safety studies of inhaled treatments in COPD [8,9]. Assuming a within-patient standard deviation of 6.7 bpm, a mean difference between treatments of 0 bpm, an upper non-inferiority margin of 5 bpm and a one-sided significance level of 2.5%, 40 evaluable patients (8 per sequence) ensured 90% power to demonstrate the non-inferiority of BDP/FF via the DPI relative to BDP/FF via the pMDI at each dose level.
Evaluating the safety of COPD medications: An evidence-based review
2013, ChestCitation Excerpt :Most safety assessments for β2-agonists have been conducted in patients with asthma, with relatively few studies in patients with COPD. Small studies in patients with COPD have demonstrated no difference between levalbuterol or albuterol compared with placebo in terms of cardiovascular adverse events and overall suggest these drugs are well tolerated (Table 2).19,23,25–31 However, these studies are limited by their size and duration.23,27–31
Salmeterol-Fluticasone: The Role Revisited
2021, Journal of Association of Physicians of India
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: [email protected]).
The studies reported in this manuscript were supported by GlaxoSmithKline.